All Title Author
Keywords Abstract

PLOS ONE  2013 

Pharmacometabolomics Reveals Racial Differences in Response to Atenolol Treatment

DOI: 10.1371/journal.pone.0057639

Full-Text   Cite this paper   Add to My Lib


Antihypertensive drugs are among the most commonly prescribed drugs for chronic disease worldwide. The response to antihypertensive drugs varies substantially between individuals and important factors such as race that contribute to this heterogeneity are poorly understood. In this study we use metabolomics, a global biochemical approach to investigate biochemical changes induced by the beta-adrenergic receptor blocker atenolol in Caucasians and African Americans. Plasma from individuals treated with atenolol was collected at baseline (untreated) and after a 9 week treatment period and analyzed using a GC-TOF metabolomics platform. The metabolomic signature of atenolol exposure included saturated (palmitic), monounsaturated (oleic, palmitoleic) and polyunsaturated (arachidonic, linoleic) free fatty acids, which decreased in Caucasians after treatment but were not different in African Americans (p<0.0005, q<0.03). Similarly, the ketone body 3-hydroxybutyrate was significantly decreased in Caucasians by 33% (p<0.0001, q<0.0001) but was unchanged in African Americans. The contribution of genetic variation in genes that encode lipases to the racial differences in atenolol-induced changes in fatty acids was examined. SNP rs9652472 in LIPC was found to be associated with the change in oleic acid in Caucasians (p<0.0005) but not African Americans, whereas the PLA2G4C SNP rs7250148 associated with oleic acid change in African Americans (p<0.0001) but not Caucasians. Together, these data indicate that atenolol-induced changes in the metabolome are dependent on race and genotype. This study represents a first step of a pharmacometabolomic approach to phenotype patients with hypertension and gain mechanistic insights into racial variability in changes that occur with atenolol treatment, which may influence response to the drug.


[1]  Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, et al. (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365: 217–223.
[2]  Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, et al. (2010) Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens 24: 336–344.
[3]  Ma J, Stafford RS (2008) Screening, treatment, and control of hypertension in US private physician offices, 2003–2004. Hypertension 51: 1275–1281.
[4]  Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201–207.
[5]  Messerli FH, Bangalore S, Julius S (2008) Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 117: 2706–2715; discussion 2715.
[6]  Corona G, Rizzolio F, Giordano A, Toffoli G (2012) Pharmaco-metabolomics: an emerging “omics” tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets. J Cell Physiol 227: 2827–2831.
[7]  Johnson CH, Gonzalez FJ (2012) Challenges and opportunities of metabolomics. J Cell Physiol 227: 2975–2981.
[8]  Kaddurah-Daouk R, Krishnan KR (2009) Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 34: 173–186.
[9]  Kaddurah-Daouk R, Kristal BS, Weinshilboum RM (2008) Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 48: 653–683.
[10]  Patti GJ, Yanes O, Siuzdak G (2012) Innovation: Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 13: 263–269.
[11]  Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, et al. (2011) Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 89: 97–104.
[12]  Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng ZB, Wiest MM, et al. (2011) Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS One 6: e25482.
[13]  Trupp M, Zhu H, Wikoff WR, Baillie RA, Zeng ZB, et al. (2012) Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. PLoS One 7: e38386.
[14]  Abo R, Hebbring S, Ji Y, Zhu H, Zeng ZB, et al. (2012) Merging pharmacometabolomics with pharmacogenomics using ‘1000 Genomes’ single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics 22: 247–253.
[15]  Kaddurah-Daouk R, Boyle SH, Matson W, Sharma S, Matson S, et al. (2011) Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatry 1: e26.
[16]  Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, et al. (2009) Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 157: 442–449.
[17]  Scholz M, Fiehn O (2007) SetupX–a public study design database for metabolomic projects. Pac Symp Biocomput 169–180.
[18]  Fiehn O, Wohlgemuth G, Scholz M, Kind T, Lee do Y, et al. (2008) Quality control for plant metabolomics: reporting MSI-compliant studies. Plant J 53: 691–704.
[19]  Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, et al. (2008) Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One 3: e3583.
[20]  Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.
[21]  Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100: 9440–9445.
[22]  Stone EA, Ayroles JF (2009) Modulated modularity clustering as an exploratory tool for functional genomic inference. PLoS Genet 5: e1000479.
[23]  Barupal DK, Haldiya PK, Wohlgemuth G, Kind T, Kothari SL, et al. (2012) MetaMapp: mapping and visualizing metabolomic data by integrating information from biochemical pathways and chemical and mass spectral similarity. BMC Bioinformatics 13: 99.
[24]  Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498–2504.
[25]  Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, et al. (1999) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 27: 29–34.
[26]  Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, et al. (2001) Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J 1: 167–170.
[27]  Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, et al. (2009) Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A 106: 3698–3703.
[28]  Hartman AL, Lough DM, Barupal DK, Fiehn O, Fishbein T, et al. (2009) Human gut microbiome adopts an alternative state following small bowel transplantation. Proc Natl Acad Sci U S A 106: 17187–17192.
[29]  Rogers DJ, Tanimoto TT (1960) A Computer Program for Classifying Plants. Science 132: 1115–1118.
[30]  Saifer A, Goldman L (1961) The free fatty acids bound to human serum albumin. Journal of Lipid Research 2: 3.
[31]  Day JL, Simpson N, Metcalfe J, Page RL (1979) Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Br Med J 1: 77–80.
[32]  Deacon SP (1978) The effects of atenolol and propranolol upon lipolysis. Br J Clin Pharmacol 5: 123–125.
[33]  Hostetler KY, Matsuzawa Y (1981) Studies on the mechanism of drug-induced lipidosis. Cationic amphiphilic drug inhibition of lysosomal phospholipases A and C. Biochem Pharmacol 30: 1121–1126.
[34]  Pappu AS, Yazaki PJ, Hostetler KY (1985) Inhibition of purified lysosomal phospholipase A1 by beta-adrenoceptor blockers. Biochem Pharmacol 34: 521–524.
[35]  Brilakis ES, Khera A, McGuire DK, See R, Banerjee S, et al. (2008) Influence of race and sex on lipoprotein-associated phospholipase A2 levels: Observations from the Dallas Heart Study. Atherosclerosis 199: 110–115.
[36]  Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, et al. (2006) Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol 9: 138–143.
[37]  Sanchez-Roman I, Gomez J, Naudi A, Ayala V, Portero-Otin M, et al. (2010) The beta-blocker atenolol lowers the longevity-related degree of fatty acid unsaturation, decreases protein oxidative damage, and increases extracellular signal-regulated kinase signaling in the heart of C57BL/6 mice. Rejuvenation Res 13: 683–693.
[38]  Sui J, Zhang J, Tan TL, Ching CB, Chen WN (2008) Comparative proteomics analysis of vascular smooth muscle cells incubated with S- and R-enantiomers of atenolol using iTRAQ-coupled two-dimensional LC-MS/MS. Mol Cell Proteomics 7: 1007–1018.
[39]  Keyes SR, Cinti DL (1980) Biochemical properties of cytochrome b5-dependent microsomal fatty acid elongation and identification of products. J Biol Chem 255: 11357–11364.
[40]  Reddy VV, Kupfer D, Caspi E (1977) Mechanism of C-5 double bond introduction in the biosynthesis of cholesterol by rat liver microsomes. J Biol Chem 252: 2797–2801.
[41]  Stanley JC (1981) The glucose-fatty acid-ketone body cycle. Role of ketone bodies as respiratory substrates and metabolic signals. Br J Anaesth 53: 131–136.
[42]  Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, et al. (2008) Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57: 203–209.
[43]  Johnson JA (2008) Ethnic Differences in Cardiovascular Drug Response. Circulation 118: 1383–1393.
[44]  Krauss RM, Mangravite LM, Smith JD, Medina MW, Wang D, et al. (2008) Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 117: 1537–1544.
[45]  Gupta AK, Poulter NR, Dobson J, Eldridge S, Cappuccio FP, et al. (2010) Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial. Am J Hypertens 23: 1023–1030.
[46]  Sergeant S, Hugenschmidt CE, Rudock ME, Ziegler JT, Ivester P, et al. (2011) Differences in arachidonic acid levels and fatty acid desaturase (FADS) gene variants in African Americans and European Americans with diabetes or the metabolic syndrome. Br J Nutr 1–9.
[47]  Barakat H, Hickner RC, Privette J, Bower J, Hao E, et al. (2002) Differences in the lipolytic function of adipose tissue preparations from Black American and Caucasian women. Metabolism 51: 1514–1518.
[48]  Berk ES, Kovera AJ, Boozer CN, Pi-Sunyer FX, Albu JB (2006) Metabolic Inflexibility in Substrate Use Is Present in African-American But Not Caucasian Healthy, Premenopausal, Nondiabetic Women. Journal of Clinical Endocrinology & Metabolism 91: 4099–4106.
[49]  Kurnik D, Li C, Sofowora GG, Friedman EA, Muszkat M, et al. (2008) Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenet Genomics 18: 895–902.
[50]  Cushman WC, Reda DJ, Perry HM, Williams D, Abdellatif M, et al. (2000) Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 160: 825–831.
[51]  Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, et al. (1993) Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 328: 914–921.


comments powered by Disqus